Reprogramming of a human induced pluripotent stem cell (iPSC) line (IBMSi012-A) from an early-onset Parkinson's disease patient harboring a homozygous p.D331Y mutation in the PLA2G6 gene. 2019

Yu-Che Cheng, and Han-I Lin, and Shih-Han Syu, and Huai-En Lu, and Ching-Ying Huang, and Chin-Hsien Lin, and Patrick C H Hsieh
Institute of Biomedical Science, Academia Sinica, Taipei, Taiwan.

A recessive mutation in PLA2G6, which is known to cause a heterogeneous neurodegenerative clinical spectrum, has recently been shown to be responsible for autosomal-recessive familial forms of Parkinson's disease (PD). Here, we generated induced pluripotent stem cells (iPSCs) from the peripheral blood mononuclear cells of a female patient with a homozygous PLA2G6 c.991G > T (p.D331Y) mutation by using the Sendai-virus delivery system. The resulting iPSCs showed pluripotency confirmed by immunofluorescent staining for pluripotency markers and differentiated into the 3 germ layers in vivo. This cellular model will provide a good resource for further pathophysiological studies of PD.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005260 Female Females
D006720 Homozygote An individual in which both alleles at a given locus are identical. Homozygotes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Yu-Che Cheng, and Han-I Lin, and Shih-Han Syu, and Huai-En Lu, and Ching-Ying Huang, and Chin-Hsien Lin, and Patrick C H Hsieh
December 2020, Stem cell research,
Yu-Che Cheng, and Han-I Lin, and Shih-Han Syu, and Huai-En Lu, and Ching-Ying Huang, and Chin-Hsien Lin, and Patrick C H Hsieh
June 2025, Stem cell research,
Yu-Che Cheng, and Han-I Lin, and Shih-Han Syu, and Huai-En Lu, and Ching-Ying Huang, and Chin-Hsien Lin, and Patrick C H Hsieh
January 2024, Stem cell research,
Yu-Che Cheng, and Han-I Lin, and Shih-Han Syu, and Huai-En Lu, and Ching-Ying Huang, and Chin-Hsien Lin, and Patrick C H Hsieh
April 2020, Stem cell research,
Yu-Che Cheng, and Han-I Lin, and Shih-Han Syu, and Huai-En Lu, and Ching-Ying Huang, and Chin-Hsien Lin, and Patrick C H Hsieh
December 2019, Stem cell research,
Yu-Che Cheng, and Han-I Lin, and Shih-Han Syu, and Huai-En Lu, and Ching-Ying Huang, and Chin-Hsien Lin, and Patrick C H Hsieh
August 2020, Stem cell research,
Yu-Che Cheng, and Han-I Lin, and Shih-Han Syu, and Huai-En Lu, and Ching-Ying Huang, and Chin-Hsien Lin, and Patrick C H Hsieh
April 2022, Stem cell research,
Yu-Che Cheng, and Han-I Lin, and Shih-Han Syu, and Huai-En Lu, and Ching-Ying Huang, and Chin-Hsien Lin, and Patrick C H Hsieh
December 2024, Stem cell research,
Yu-Che Cheng, and Han-I Lin, and Shih-Han Syu, and Huai-En Lu, and Ching-Ying Huang, and Chin-Hsien Lin, and Patrick C H Hsieh
January 2017, Stem cell research,
Yu-Che Cheng, and Han-I Lin, and Shih-Han Syu, and Huai-En Lu, and Ching-Ying Huang, and Chin-Hsien Lin, and Patrick C H Hsieh
October 2024, Stem cell research,
Copied contents to your clipboard!